Legal Representation
Attorney
Julianne Abelman
USPTO Deadlines
Next Deadline
132 days remaining
Statement of Use Due - Extension 1 Granted
Due Date
November 19, 2025
Extension Available
Until November 19, 2025
Application History
18 eventsDate | Code | Type | Description |
---|---|---|---|
Mar 8, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
Mar 8, 2025 | EX1G | S | SOU EXTENSION 1 GRANTED |
Mar 7, 2025 | EXT1 | S | SOU EXTENSION 1 FILED |
Mar 7, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
Nov 19, 2024 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
Oct 8, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
Oct 8, 2024 | PUBO | A | PUBLISHED FOR OPPOSITION |
Sep 18, 2024 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
Aug 31, 2024 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER |
Aug 16, 2024 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
Aug 16, 2024 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
Aug 16, 2024 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
Jun 26, 2024 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
Jun 26, 2024 | GNRT | F | NON-FINAL ACTION E-MAILED |
Jun 26, 2024 | CNRT | R | NON-FINAL ACTION WRITTEN |
Jun 25, 2024 | DOCK | D | ASSIGNED TO EXAMINER |
Jan 16, 2024 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
Nov 25, 2023 | NWAP | I | NEW APPLICATION ENTERED |
Detailed Classifications
Class 005
Pharmaceutical preparations for human use with progesterone as active ingredient for estrogen replacement therapy in the perimenopausal and postmenopausal period and for use for disorders due to progesterone insufficiency
Classification
International Classes
005